共 16 条
[1]
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
[J].
ARTHRITIS AND RHEUMATISM,
2004, 50 (11)
:3580-3590
[2]
DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
[J].
ARTHRITIS AND RHEUMATISM,
1992, 35 (06)
:630-640
[4]
The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus
[J].
ARTHRITIS AND RHEUMATISM,
1996, 39 (03)
:363-369
[6]
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
[J].
ARTHRITIS AND RHEUMATISM,
2007, 56 (04)
:1263-1272
[7]
Assessing patients with lupus: towards a drug responder index
[J].
RHEUMATOLOGY,
1999, 38 (11)
:1045-1049
[10]
B cell depletion as a novel treatment for systemic lupus erythematosus - A phase I/II dose-escalation trial of rituximab
[J].
ARTHRITIS AND RHEUMATISM,
2004, 50 (08)
:2580-2589